← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Progenics Pharmaceuticals, Inc.
Tarrytown, NY
$60,205,150
Total funding
44
Grants
Funding over time
peak $10.2M · FY2005–12$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$60,205,150 · 44
By mechanism
R44$22,140,329 · 9
R43$10,462,145 · 21
U19$9,177,894 · 5
R01$7,954,968 · 3
P01$5,784,203 · 4
RC4$4,143,652 · 1
Investigators at Progenics Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Novel, Non-antibiotic Therapy for Clostridium difficile-Associated Disease$4,143,652
RC4 · FY2010 · AI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$3,028,502
U19 · FY2006 · AI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$2,987,862
U19 · FY2008 · AI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,860,535
P01 · FY2009 · AI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,781,188
P01 · FY2010 · AI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$2,544,127
U19 · FY2007 · AI
HIV Vaccine Design and Development Team$2,090,481
R01 · FY2001 · AI
HIV Vaccine Design and Development Team$1,974,283
R01 · FY2000 · AI
Core--Manufacturing, Quality And Analytical$1,303,114
U19 · FY2007 · AI
Core--Manufacturing, Quality And Analytical$1,224,830
U19 · FY2008 · AI
PA-50/PA-41 antitoxin antibody therapy for C. difficile infection$1,128,535
R01 · FY2012 · AI
PA-50/PA-41 antitoxin antibody therapy for C. difficile infection$1,123,669
R01 · FY2011 · AI
HIV-1 Therapy with CCR5 mAB PRO 140-Overview$1,066,099
U19 · FY2005 · AI
Humanized PRO 140 for CCR5-Targeted Therapy of HIV$1,062,268
R44 · FY2005 · AI
Humanized PRO 140 for CCR5-Targeted Therapy of HIV$1,034,766
R44 · FY2004 · AI
Core--Manufacturing, Quality And Analytical$1,031,541
U19 · FY2006 · AI
Development of Hepatitis C Virus Inhibitors$1,030,553
R44 · FY2007 · AI
Development of Hepatitis C Virus Inhibitors$1,001,572
R44 · FY2006 · AI
Transgenic Production of CD4-IgG2 for HIV Therapy$1,000,000
R44 · FY2003 · AI
Human PSMA MAb Radioimmunotherapy for Prostate Cancer$1,000,000
R44 · FY2006 · CA